VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced the publication of a peer-reviewed study in Critical Care Medicine demonstrating that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and the need for renal replacement therapy in patients with sepsis and septic shock. The findings could significantly impact how clinicians manage these life-threatening conditions, offering a tool for early risk stratification and intervention.
The study, which involved patients with sepsis and septic shock, found significantly higher Nu.Q NETs H3.1 levels in those with septic shock compared to sepsis alone. Moreover, the biomarker exhibited a dose-response relationship with acute kidney injury severity, indicating that higher levels correlate with worse outcomes. The journal also published an independent editorial examining H3.1 nucleosomes as a potential marker of NET-mediated organ injury, underscoring the scientific interest in this mechanism.
Sepsis is a leading cause of hospital mortality, with outcomes often depending on timely and appropriate treatment. The ability to predict which patients are at higher risk for deterioration could allow clinicians to allocate resources more effectively and personalize therapeutic strategies. VolitionRx believes that Nu.Q NETs could be used to anticipate disease progression, guide treatment decisions, and monitor patients over time, both in acute settings like sepsis and in chronic conditions associated with NETosis.
Dr. Andrew Retter, Medical Consultant at Volition, emphasized the potential impact: “Introducing Nu.Q NETs into hospitals, as a treatable, trackable trait, could lead to new ways of treating sepsis, improve patient survival and the quality of life of survivors.” This statement highlights the company's vision for the biomarker as a routine clinical tool.
The commercial potential is substantial. Volition cites a total addressable market of $2.8 billion for Nu.Q NETs technology. The company is already in ongoing commercial and licensing discussions, and these latest findings add to a growing body of evidence supporting the test's clinical utility. The publication in a top critical care journal and the accompanying editorial lend credibility to the biomarker's potential.
For more information, see the full press release at https://ibn.fm/RErhc.
